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Abstract 
Breakdown of the blood–brain barrier (BBB) or inner blood–retinal barrier (BRB), induced by pathologically elevated 
levels of vascular endothelial growth factor (VEGF) or other mediators, can lead to vasogenic edema and significant 
clinical problems such as neuronal morbidity and mortality, or vision loss. Restoration of the barrier function with 
corticosteroids in the brain, or by blocking VEGF in the eye are currently the predominant treatment options for brain 
edema and diabetic macular edema, respectively. However, corticosteroids have side effects, and VEGF has important 
neuroprotective, vascular protective and wound healing functions, implying that long-term anti-VEGF therapy may 
also induce adverse effects. We postulate that targeting downstream effector proteins of VEGF and other media-
tors that are directly involved in the regulation of BBB and BRB integrity provide more attractive and safer treatment 
options for vasogenic cerebral edema and diabetic macular edema. The endothelial cell-specific protein plasma-
lemma vesicle-associated protein (PLVAP), a protein associated with trans-endothelial transport, emerges as candi-
date for this approach. PLVAP is expressed in a subset of endothelial cells throughout the body where it forms the 
diaphragms of caveolae, fenestrae and trans-endothelial channels. However, PLVAP expression in brain and eye barrier 
endothelia only occurs in pathological conditions associated with a compromised barrier function such as cancer, 
ischemic stroke and diabetic retinopathy. Here, we discuss the current understanding of PLVAP as a structural compo-
nent of endothelial cells and regulator of vascular permeability in health and central nervous system disease. Besides 
providing a perspective on PLVAP identification, structure and function, and the regulatory processes involved, we 
also explore its potential as a novel therapeutic target for vasogenic cerebral edema and retinal macular edema.
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Background
Integrity of the blood–brain barrier (BBB) is essential to 
maintain a proper microenvironment for neuronal cells 
to function. Similar to the BBB, the inner blood–retinal 
barrier (BRB) protects the retina that consists of layers of 
specialized neurons. Breakdown of the BBB and BRB, as 
occurs in pathological conditions such as trauma, acute 
ischemic stroke [1], brain tumors [2] and diabetic retin-
opathy [3], causes leakage of fluid and plasma proteins 
from the vasculature into the surrounding tissue and 
subsequently vasogenic edema formation. Edema forma-
tion in the brain and eye is associated with neuronal and 
retinal dysfunction, causing severe mortality and loss of 
visual acuity, respectively [4, 5]. Given the similarities 
between the BBB and BRB, promising novel therapeutic 
candidates that prevent disruption of the BRB are also 
interesting targets in the treatment of BBB-related neu-
rological diseases.
Corticosteroids are the main treatment option for brain 
edema, but therapy is associated with severe side effects 
[6]. Restoration of the barrier function via inhibition of 
vascular endothelial growth factor-A (VEGF), a potent 
inducer of angiogenesis and vascular permeability, is cur-
rently an effective treatment for diabetic macular edema 
(DME) and a promising treatment option for vasogenic 
brain edema [4, 7–10]. However, anti-VEGF therapy still 
has its limitations, including systemic side effects, a sub-
optimal response in a subset of macular edema patients, 
and the need for frequent and long-term therapy [11]. In 
addition, a large number of studies has identified roles of 
VEGF in wound healing and neuronal cell and retinal cell 
survival [12–18]. This raises significant concerns about 
long-term anti-VEGF therapy, indicating that alternative 
treatment options are needed. For such alternatives, tar-
geting downstream effectors of VEGF, or unraveling spe-
cific cellular response pathways of barrier endothelium 
to VEGF, corticosteroids or other mediators, may lead to 
more specific and safer treatment options for vasogenic 
cerebral edema and DME.
Many cell types are involved in the breakdown of the 
BBB and BRB, but endothelial cells play a central role in 
this process. Under normal physiological conditions, the 
restrictive properties of barrier endothelial cells are the 
result of an extensive junctional network between cells, 
limited number of pinocytotic vesicles and absence of 
fenestrations [19, 20]. Generally, there are two main path-
ways by which VEGF and other mediators induce break-
down of the barrier: (1) increased paracellular transport 
by altering the junctional network between cells and (2) 
increased transcellular transport by elevated vesicular 
transcytosis. In the literature, the paracellular pathway is 
generally regarded to be the most important factor in ret-
inal edema formation, but a growing number of studies 
suggest that increased transport of macromolecules via 
the transcellular pathway constitutes an alternative or 
additional mechanism of vasogenic edema formation (as 
reviewed in [3, 21]).
The Pathologische Anatomie Leiden-Endothelium 
(PAL-E) antibody, which binds an endothelial cell-spe-
cific marker expressed outside the brain and eye, has 
been widely used as a histochemical vascular marker in 
frozen tissue sections [22]. Moreover, PAL-E identifies 
vessels that have lost BBB or BRB properties [22–25]. 
Although its molecular target has remained unknown 
for decades, it is now well established that PAL-E recog-
nizes plasmalemma vesicle-associated protein (PLVAP 
also called PV-1), a structural component of caveolae, 
fenestrae and trans-endothelial channels (TECs) (Fig. 1) 
[26, 27]. In recent years, significant progress has been 
made in the understanding of molecular mechanisms 
that are involved in the association of PLVAP and micro-
vascular leakage. A key role of PLVAP has been eluci-
dated in VEGF-induced BRB permeability by promoting 
trans-endothelial transport [28].
In the present review, we discuss the history of the 
identification of PLVAP, focus on the current understand-
ing of PLVAP as regulator of vascular permeability, and 
explore its potential as novel target for vasogenic cerebral 
edema and DME.
The history of the identification of PLVAP
The endothelium consists of a heterogeneous population 
of cells with diverse functions across the entire vascular 
system, but also within one vascular bed. Depending on 
different needs for controlled regulation of vascular per-
meability for water and solutes, the endothelium may be 
continuous, fenestrated or discontinuous (as reviewed 
in [29]). Mainly due to its specificity for endothelium 
and its ability to discriminate between certain subsets of 
endothelial cells, the PAL-E antibody has been a widely 
used vascular marker. PAL-E was generated over 30 years 
ago by injection of human melanoma lymph node metas-
tases into mice [22]. PAL-E prominently stains endothe-
lial cells of capillaries, medium-sized veins, venules and 
splenic sinusoids, but does not or only weakly stains 
arteries, arterioles, large veins and lymphatic vessels in 
tissues of mammals such as human or rabbit (Table  1) 
[22]. Therefore, in combination with a general vascu-
lar marker such as CD31, PAL-E is useful to distinguish 
between vessels of lymphatic or vascular origin. The 
MECA-32 antibody, which was derived from immuniz-
ing rats with murine lymph node stroma, shows similar 
staining patterns in mouse tissues as PAL-E in humans, 
and is now known to recognize the murine variant of the 
PAL-E antigen [30, 31]. However, it should be noted that 
Page 3 of 17Bosma et al. Fluids Barriers CNS  (2018) 15:24 
MECA-32 but not PAL-E recognizes arterioles and large 
veins [22, 30].
In brain, PAL-E prominently stains the fenestrated 
endothelium of the choroid plexus, but PAL-E stain-
ing is absent in continuous endothelium of the cerebral 
cortex and cerebellum (Table 2) [23, 32]. Similar staining 
patterns are observed in the eye where PAL-E stains the 
fenestrated endothelium of the choriocapillaris and cili-
ary processes, but not the continuous barrier capillaries 
of the optic nerve, retina, iris and ciliary muscle (Table 2) 
[23, 24, 33, 34]. These findings indicate that the PAL-E 
antigen is absent in endothelium with BBB, BRB or other 
blood–tissue barrier properties. De novo expression of 
the PAL-E antigen in endothelium of the BBB and BRB 
typically occurs under pathological conditions associ-
ated with barrier disruption such as brain ischemia, can-
cer and diabetic retinopathy [22, 23, 25, 35–38]. Notably, 
expression of the PAL-E antigen in retinal vessels posi-
tively correlates with focal microvascular leakage of 
plasma proteins [25]. This indicates that the PAL-E anti-
gen may actively participate in pathological BRB and BBB 
breakdown, underscoring the importance of resolving its 
molecular identity.
Despite the fact that the molecular target of PAL-E 
remained an enigma for years, Schlingemann et  al. [22] 
demonstrated in the mid-1980s that PAL-E is localized 
at the exterior of intracellular endothelial vesicles using 
immunoelectron microscopy (Fig. 1). On the basis of this 
specific localization and its absence in barrier endothe-
lium, it was suggested that the PAL-E antigen is involved 
in trans-endothelial transport [23]. However, rather than 
having a universal association with endothelial vesicles, 
PAL-E is associated with a sub-population of vesicles that 
show a similar distribution as the albumin receptor in 
mice [23, 39].
The first study aimed at the elucidation of the molecu-
lar target of PAL-E was based on protein purification and 
tandem mass spectrometry analysis of tryptic peptides 
and identified a secreted form of vimentin as molecu-
lar target of PAL-E [40]. However, this finding was later 
challenged because a different antibody isotype than 
the original PAL-E antibody was used [22, 40]. In addi-
tion, the antibody was produced from ascites fluid which 
may have introduced impurities during the antibody 
preparation steps [27, 40]. Afterwards, Niemela et  al. 
[27] generated the 174/2 antibody, by injection of ves-
sels of human lymph nodes in mice and fusing the lym-
phocytes after immunization with myeloma cells, which 
recognizes PLVAP. With the use of double immunostain-
ing, Niemela et  al. [27] provided evidence that PAL-E 
and 174/2 recognize the same antigen and not vimen-
tin as was reported earlier. Jaalouk et al. [41] questioned 
these findings since PAL-E and 174/2 did not inhibit each 
other in competitive staining experiments. On the other 
hand, they showed by epitope mapping that PAL-E rec-
ognizes a VEGF-binding site of neuropilin-1 (NRP-1) 
[41]. However, NRP-1 is also expressed in neuronal, epi-
thelial and immune cells [42–44], which is in contrast to 
the vast number of publications that show that PAL-E 
and MECA-32 are endothelial cell-specific markers. The 
lack of competitive antigen binding in the study of Nie-
mela et al. [27] may be explained by the notion that the 
different antibodies recognize different epitopes in the 
PLVAP molecule. While 174/2 can be used to detect 
PLVAP in cell lysates under reducing conditions, PAL-E 
only detects proteins under native conditions [27]. By 
Fig. 1 The PAL-E antibody stains endothelial vesicles. Immunogold labelling of cultured human endothelial cells from umbilical veins shows that 
the PAL-E antigen is associated with the exterior of endothelial vesicles (arrowheads and inset) (Reprinted from [22])
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performing cross-immunoprecipitations with 174/2 and 
PAL-E, Niemela et al. showed that PAL-E completely pre-
vented binding of 174/2 to its molecular target (which 
in the control samples recognized the 120  kDa PLVAP 
homodimer), whereas PAL-E still recognized a protein 
with a molecular weight of 85 kDa after preclearing the 
protein lysate with 174/2 [27]. Therefore, it is plausi-
ble that PAL-E recognizes both mature N-glycosylated 
PLVAP and a degradation product, whereas 174/2 rec-
ognizes an antigenic epitope within the glycan antennae 
of PLVAP [27]. In conclusion, three different molecular 
targets of PAL-E have been proposed in the past, vimen-
tin, PLVAP and NRP-1. However, as discussed above, the 
results of Niemela et al. [27] were the most convincing.
More recently, the same research group as Niemela 
et al. [27] provided the final evidence that PAL-E recog-
nizes PLVAP and not NRP-1 [45]. With the use of double 
staining, Keuschnigg et al. [45] showed that both PLVAP 
and NRP-1 colocalize with the PAL-E antigen in human 
tissues. However, significantly different staining patterns 
were obtained with PAL-E and anti-NRP-1 in heart and 
liver, whereas the staining patterns of PAL-E and 174/2 
were identical in all human tissues analyzed. To further 
analyze the association of PAL-E with NRP-1 and PLVAP, 
Keuschnigg et  al. [45]  transfected PLVAP and NRP-1 in 
HEK EBNA cells and revealed that cells transfected with 
PLVAP bind PAL-E and 174/2, whereas cells transfected 
with NRP-1 only bind anti-NRP-1. Finally, it was shown 
with co-immunoprecipitation studies that PLVAP and 
NRP-1 physically interact, explaining the contradict-
ing findings of Jaalouk et al. [41, 45]. In an earlier study, 
Keuschnigg et al. [46] showed that PLVAP also physically 
interacts with vimentin, which may explain the findings 
of Xu et  al. [40]. Taken together, these studies clearly 
demonstrated that PAL-E recognizes PLVAP.
PLVAP structure and function
PLVAP is the only known molecular component of fenes-
tral diaphragms (FDs) and stomatal diaphragms (SDs) 
[47, 48]. These diaphragms form cap-like structures 
that bridge the opening of caveolae, fenestrae and TECs 
(Fig.  2). Caveolae, which are characterized by the pres-
ence of caveolin-1, are spherical or flask-shaped mem-
brane vesicles that play a role in transcytosis [49, 50]. 
Fenestrae and TECs are pore-like structures that allow 
rapid exchange of molecules between the circulation and 
the underlying tissue [29]. Interestingly, this nicely fits 
the initial observations of Schlingemann et al. that PAL-E 
staining is localized to the exterior of endothelial vesicles 
(Fig. 1), and is in line with their original hypothesis that 
the PAL-E antigen is involved in transcellular transport 
[22, 23].
Table 1 PLVAP expression in  non-barrier endothelium 
detected with PAL-E (human tissue) and MECA-32 (mouse 
tissue)
Grading: −, no staining; ±, variable staining; +, positive staining; ND, not 
determined
a Non-glomerular blood vessel endothelium
b Only reported in embryonic mouse tissue (E16.5)
PAL-E MECA-32 References
Vascular system
Arteries
 Large elastic – ND [22]
 Medium-sized and small ± or − ND [22]
Arterioles ± or − + [22, 30]
Capillaries + ± [22, 30]
Venules + + [22, 30]
Veins
 Medium-sized and small + ND [22]
 Large elastic − + [22, 30]
Lymphatic system
Lymphatic vessels − − [22, 118]
Lymph node
 Subcapsular sinus ND + [60]
Sinus histiocytes − ND [22]
Kidney
Adult kidney
 Glomeruli − ± [30, 119]
 Endotheliuma + + [30, 119]
Fetal kidney
 Glomeruli + ND [30, 119]
 Endotheliuma + ND [30, 119]
Liver
Adult liver
 Sinusoids − ND [22]
  Periportal area + ND [22]
 Fetal liver
  Sinusoids + + [58, 98]
Muscle
Cardiac muscle ± + [30, 33]
Skeletal muscle ± + [30, 33]
Bladder + ND [33]
Gut + ND [33]
Other tissues
Lung ND + [30, 55]
Pancreas ND + [30, 58]
Spleen
 Sinusoids + + [22, 30]
Skin + +b [23, 55]
Thymus + + [30, 45]
Intestine ND + [30, 55, 58]
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PLVAP is an endothelial cell-specific type II membrane 
N-glycosylated glycoprotein with a molecular weight 
of approximately 55–65  kDa, that forms homodimers 
in situ [48, 51, 52]. PLVAP consists of a short intracellular 
domain (27 amino acids), a single span transmembrane 
domain and a large extracellular domain (380 amino 
acids) [48, 52]. Conserved regions are not found within 
the intracellular domain across species [52], but two short 
identical amino acids stretches of approximately 7–8 
amino acids are present within the intracellular domain, 
of which one functions as a putative caveolin-1-binding 
site [49, 53]. In contrast to the intracellular domain, the 
Table 2 PLVAP expression in brain and eye endothelia detected with PAL-E (human tissue) and MECA-32 (mouse tissue)
Grading: −, no staining; ±, variable staining; +, positive staining; ND, not determined; BBB, blood–brain barrier; BRB, blood–retinal barrier
PAL-E MECA-32 Type of endothelium References
Brain
Adult brain tissues
Parenchyma − − BBB [23, 30]
Cerebellum − ND BBB [23]
Cerebral cortex − ND BBB [23]
Medulla − ND BBB [23]
Meninges − ND BBB [23]
Midbrain − ND BBB [23]
Spinal cord − ND BBB [23]
Choroid plexus
 Lateral ventricle + + Fenestrated [23, 30]
 Fourth ventricle + + Fenestrated [23, 30]
Dura mater + + Fenestrated [23, 30]
Pituitary gland + + Fenestrated [23, 30]
Fetal brain tissues + + Immature BBB [30, 38]
Brain tumor tissues
 Primary brain tumors + + Disrupted BBB [23, 35, 38]
 Metastases + ND Disrupted BBB [23, 38]
Eye
Normal eye
Retina − − BRB [22, 24, 56, 
Van der Wijk 
et al.,  sub-
mitted]
Iris − ND Blood–ocular barrier [24, 33]
Optic nerve head
 Prelaminal region + ND Continuous [34]
 Lamina cribosa − ND BBB [34]
 Retro-laminar region − ND BBB [34]
Orbital optic nerve − ND BBB [24]
Choroid + + Fenestrated [23, 24, 56]
Ciliary process + + Fenestrated [24, 33, 56]
Ciliary muscle − − Blood–ocular barrier [24, 33, 56]
Conjunctiva + ND Fenestrated [24]
Extraocular muscle ± ND Continuous [33]
Sclera + + Continuous [24, 56]
Developing eye
Retina ND + Immature BRB [Van der Wijk 
et al., sub-
mitted]
Diabetic eye
Retina + + Disrupted BRB [25, 63]
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extracellular domain is highly conserved in mamma-
lian species and is characterized by four N-glycosylation 
sites, two coiled-coil domains and a proline-rich region 
[52]. The extracellular domain is dominated by α-helices 
which strongly argues for a rod-like structure [52].
The absence of PLVAP homologs in lower vertebrates 
that do not have SDs and FDs, and the unique expres-
sion in endothelium that contain these diaphragms sup-
port the notion that PLVAP forms SDs and FDs [49]. 
The precise organization and incorporation of PLVAP in 
SDs and FDs remains elusive. Rapid-freezing and deep-
etching electron microscopy of FDs revealed that PLVAP 
is organized in diaphragms in an octagonal wheel-like 
symmetry [49, 54]. It is hypothesized that PLVAP dimers 
form radial fibrils that are anchored in the cell membrane 
via the short intracellular tail and interweaves in a central 
mesh via the extracellular tail [49]. The bulk of PLVAP 
consists of its extracellular domain, and PLVAP dimers 
are prevented to collapse by prominent glycosylation 
near the transmembrane domain which accounts for 15% 
of the total mass of PLVAP [48]. In addition, intracellular 
connections to the cytoskeleton, which occur via direct 
binding or cytoskeletal linker molecules [46, 49], further 
stabilize PLVAP in the membrane.
PLVAP expression seems to be necessary for the bio-
genesis of diaphragms. For instance, siRNA targeting 
of PLVAP prevents de novo formation of SDs and FDs 
after phorbol myristate acetate (PMA) stimulation, 
whereas transient expression of PLVAP in endothe-
lial cells that normally lack SDs results in the forma-
tion of these diaphragms [26]. Likewise, SDs and FDs 
are absent in PLVAP-knockout mice [55–57]. However, 
other molecules are likely to be present besides PLVAP 
in diaphragms because fluffy electron-dense material 
is present in the opening of caveolae and fenestrae in 
PLVAP-knockout mice [55, 56]. Besides functioning as 
an inducer of diaphragm biogenesis, PLVAP regulates the 
number of fenestrae [55, 58] and caveolae in cells [28], in 
an VEGF-dependent manner. This indicates that PLVAP 
positively regulates the biogenesis of the structures in 
which PLVAP is expressed.
The formation of diaphragms is the only structural 
function of PLVAP as was concluded by Tkachenko 
et al. [59] on the basis of a study of two distinct vascular 
beds in lung and kidney in caveolin-1-knockout mice. 
Lung endothelium is characterized by the presence of 
caveolae and absence of fenestrae and TECs, whereas 
kidney endothelium contains caveolae, fenestrae and 
Fig. 2 PLVAP functions as physical sieve in endothelium. PLVAP homodimers assemble in diaphragms in a wheel-like fashion. The larger part of 
PLVAP is extracellular, but PLVAP dimers are stabilized in the cell membrane by prominent N-glycosylation near its transmembrane domain (not 
shown) and its intracellular connections to cytoskeletal filaments (not shown). Through this distinct organization, PLVAP regulates size-dependent 
passage of molecules. It is hypothesized that PLVAP allows the passage of molecules smaller than 6 nm in diameter only. EC endothelial cell, TEC 
transendothelial channel
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TECs. PLVAP protein levels were dramatically reduced 
in the lung vasculature but not in the kidneys of cave-
olin-1-knockout mice, suggesting that protein levels 
of PLVAP are reduced in tissues that lack the neces-
sary structures to form diaphragms [59]. The reduced 
protein levels of PLVAP were not a consequence of 
altered transcription or translation rates because these 
rates were unchanged in caveolin-1-knockout mice. 
Rather, PLVAP appeared to be degraded in lysosomes 
when caveolae were absent. Therefore, it was con-
cluded that the formation of diaphragms is the only 
structural function of PLVAP [59], but that does not 
necessarily exclude that PLVAP has other functions in 
endothelium.
PLVAP has a crucial functional role during embry-
ogenesis and postnatal physiological processes. 
C57BL/6N or C57B1/6J PLVAP-knockout mice die 
before birth as a consequence of subcutaneous edema, 
hemorrhages, and cardiac and vascular defects [55, 57]. 
In a mixed C57BL/6N/FVB-N background, PLVAP-
knockout mice are viable after birth and survive up to 
4  weeks, but these mice are significantly smaller than 
their wildtype littermates, have small kidneys, spleen 
and pancreas, and suffer from edema, anemia and 
hyperlipoproteinemia [55, 58]. Similar phenotypes were 
observed in mice with a BALB/c–C57Bl/6J–129Sv/J 
background, which survive up to 3–4 months and suffer 
from growth retardation, edema, severe hypoproteine-
mia and hypertriglyceridemia [57].
Together, these results show that PLVAP plays a cru-
cial role during the development of the cardiovascular 
system, and in postnatal physiological processes such 
as maintaining blood composition and organ homeo-
stasis. Above all, these results indicate that PLVAP may 
have an important function in the regulation of vascu-
lar permeability, which will be discussed in more detail 
later.
Interestingly, PLVAP also plays a role in immune sur-
veillance and inflammation. PLVAP has been shown to 
function as a leukocyte trafficking molecule [46]. Upon 
pro-inflammatory activation, PLVAP becomes redis-
tributed in cells, allowing the formation of transen-
dothelial channels via which leukocytes can extravasate 
[46]. Moreover, it was demonstrated that patches of 
PLVAP expression localizes together with F-actin in 
subcapsular sinus lymphatic endothelial cells of lymph 
nodes [60]. Although it is well established that PLVAP 
expression is absent in peripheral lymphatic endothe-
lium, PLVAP is exclusively expressed in the lymphatic 
system in subcapsular sinus endothelial cells of lymph 
nodes, where it functions as a molecular sieve to reg-
ulate the entry of antigens and lymphocytes into the 
lymph node [60].
Regulation of PLVAP expression
Several compounds, signaling molecules and biological 
processes have been implicated in modulating PLVAP 
expression, including VEGF [37, 61–64], angiotensin-2 
[64], PMA [26], Norrin/Wnt-mediated β-catenin sign-
aling [65–68], Notch signaling [69, 70], transforming 
growth factor-β (TGF-β) [71], inflammatory mediators 
such as tumor necrosis factor-α (TNF-α) [71], and shear 
stress [71].
VEGF, which was originally described as vascular per-
meability factor, is a potent inducer of both vascular per-
meability and angiogenesis [72, 73]. VEGF binds to three 
different tyrosine kinase receptors termed VEGF recep-
tor 1–3 (VEGFR1–3). Of these receptors only VEGFR1 
is highly expressed in brain and retinal vessels under 
physiological conditions, whereas VEGFR2 and VEGFR3 
are also highly expressed in pathological conditions such 
as diabetic retinopathy [74, 75]. Several studies demon-
strate that VEGF positively regulates PLVAP expression. 
For instance, VEGF but not PBS injection in monkey eyes 
induces PLVAP expression in retinal vessels as shown by 
immunohistochemistry [37]. Correspondingly, PLVAP 
mRNA and protein levels are increased in mice that tran-
siently overexpress VEGF in their photoreceptors [63]. 
Moreover, VEGF stimulation of bovine retinal endothe-
lial cells dramatically increased PLVAP mRNA levels [62]. 
With the use of selective receptor-specific engineered 
variants of VEGF, it was shown that PLVAP expression is 
upregulated in a VEGFR2-dependent manner [61]. More-
over, VEGF-dependent PLVAP expression is blocked 
with inhibitors of phosphatidylinositol 3-kinase (PI3K) 
(LY294002) or p38 mitogen-activated protein kinase 
(p38MAPK) (SB203580) [61]. Together, these results 
provide evidence that VEGFR2 signaling induces PLVAP 
expression in a P13K- or p38MAPK-dependent manner.
In contrast, one study showed that a VEGFR2 inhibi-
tor increased PLVAP protein levels in lungs of caveo-
lin-1-knockout mice, leading to the suggestion by the 
authors that PLVAP expression is negatively regulated 
by VEGF [76]. Notably, the VEGFR2 inhibitor did not 
alter PLVAP protein levels in wild-type mice. This rather 
contradictory result may be explained by the notion that 
VEGFR2 signaling is localized within and dependent on 
the caveolar compartment [77, 78]. Thus, decreased lev-
els of caveolae in caveolin-1-knockout mice may have led 
to dysregulated VEGF signaling.
PLVAP as regulator of vascular permeability
The specific tissue distribution of PAL-E  antigen and 
the association of PLVAP with diaphragms of cave-
olae, fenestrae and TECs has intrigued many research-
ers to study its role in vascular permeability. Although 
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PLVAP plays a crucial role in maintaining basal vascular 
permeability in a certain subset of endothelial cells (as 
described in detail below), its expression in the BBB and 
BRB is linked with pathological breakdown of the barrier. 
Here, we provide a comprehensive overview of the cur-
rent knowledge regarding the role of PLVAP in vascular 
permeability. After a brief general introduction in vascu-
lar permeability and mechanisms of BBB and BRB break-
down, we first discuss how PLVAP modulates vascular 
permeability in non-barrier endothelium, before focusing 
on its role in the BBB and BRB and their breakdown in 
pathological conditions.
Mechanism of endothelial barrier breakdown: increased 
vascular permeability
The formation and maintenance of a functional BBB and 
BRB is highly dependent on a complex interplay of multi-
ple cell types, including endothelial cells, pericytes, astro-
cytes and neurons [3, 79, 80]. As such, the BBB and BRB 
is usually referred to as a function of the neurovascular 
unit. Nevertheless, endothelial cells form the direct phys-
ical barrier between the vascular lumen and the under-
lying tissue, and therefore their characteristic phenotype 
critically governs the restrictive nature of the BBB and 
BRB.
Endothelial cells of the BBB and BRB are character-
ized by the presence of an elaborate junctional network 
between the cells, a paucity and abluminal location of 
pinocytotic vesicles and absence of fenestrations [19, 20]. 
Under normal physiological conditions, these features 
of the BBB and BRB restrict the passage of potentially 
damaging molecules into the neuronal tissue, which is 
essential for proper function, in particular axonal elec-
trical conductance [81]. However, the BBB and BRB are 
not impermeable barriers. There are two main routes via 
which molecules and solutes can cross the barrier, that is 
via paracellular and transcellular transport [82]. Paracel-
lular transport occurs via the intercellular space between 
endothelial cells and is accomplished via dynamic regu-
lation of the intercellular junctions such as tight junc-
tions and adherens junctions. Transcellular transport 
refers to transport of molecules across endothelial cells. 
Transcellular transport is accomplished via transcellular 
diffusion, membrane transporters and vesicle-like struc-
tures termed caveolae. Outside the brain and eye, this 
latter type of transport occurs either via specific recep-
tor-mediated transcytosis or non-specific fluid phase 
transcytosis. In the BBB and BRB, lipid-soluble mole-
cules can passively diffuse across the barrier. In contrast, 
water-soluble molecules and solutes are actively trans-
ported across the barrier via receptor-mediated transcy-
tosis via caveolae and solute transporters.
It is well established that both paracellular and tran-
scellular transport plays a pivotal role in pathological 
BBB and BRB breakdown [3, 83]. Although the contribu-
tion of transcellular transport in vascular permeability 
has been greatly underestimated for years, this type of 
transport mechanism is considered to play a prominent 
role in edema formation. According to Starling’s rules, 
the net movement of fluid from capillaries is dependent 
on hydrostatic and osmotic pressure of the luminal and 
extraluminal compartments. Since macromolecules can-
not easily diffuse across the membrane, we have previ-
ously hypothesized that transport of large molecules 
via the transcellular pathway is the main contributor to 
increased tissue osmotic pressure and subsequent edema 
formation in ocular conditions like DME [3].
VEGF has been shown to induce retinal permeability 
via caveolae-mediated transcytosis and not via paracel-
lular transport [84]. In addition, intravitreal injections 
of VEGF in monkey eyes shifted the distribution of 
endothelial vesicles from an abluminal localization to a 
luminal localization, without clearly altering junctional 
integrity [85]. Moreover, caveolae are increased in num-
bers after VEGF stimulation of human retinal explants 
[28] and cultured bovine retinal endothelial cells [84]. 
Collectively, these findings strongly argue for a pivotal 
role of caveolae-mediated transcytosis in VEGF-induced 
BRB permeability. Although the endothelium of the 
BBB and BRB share highly similar characteristics, it has 
not been clearly established whether caveolae-mediated 
transcytosis also plays a central role in VEGF-induced 
BBB permeability. However, a recent study shows that 
ischemia-induced permeability in the brain is also asso-
ciated with an increased number of caveolae in mouse 
endothelium [86], suggesting that similar mechanisms 
are involved.
In this review, the focus is on vasogenic edema forma-
tion which is hallmarked by a compromised barrier func-
tion of endothelial cells. However, it is important to note 
that neural edema can also develop as a result of aber-
rant ion transport while the barrier is intact. This type 
of edema formation, which is known as cytotoxic edema 
and/or ionic edema, has been extensively reviewed 
recently [87].
PLVAP in non-barrier endothelium
In non-barrier endothelium, PLVAP is expressed in 
fenestrated endothelium (with an exception of the so-
called porous endothelia in the glomerulus and liver 
sinusoidal capillaries) and in the continuous endothelium 
of skin, muscle and lung (Table 1) [22, 27, 33, 57, 88]. The 
development of genetic knockout mice that lack PLVAP 
expression has provided insight how PLVAP modulates 
endothelial barrier integrity in non-barrier endothelium. 
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Analysis of the protein content of blood plasma of 
PLVAP-knockout mice with a mixed BALB/c–C57Bl/6J–
129Sv/J background showed that total plasma protein, 
albumin and albumin/globulin ratios are significantly 
reduced with minimal electrolyte imbalance in PLVAP-
knockout mice compared to control littermates [57]. This 
reduction in blood plasma proteins was not caused by 
decreased protein production, enhanced catabolism or 
nephropathy. In contrast, significant leakage of plasma 
proteins as measured with the Evans Blue dye extrava-
sation assay was observed in organs with fenestrated 
capillaries (intestine, kidney, pancreas), whereas only a 
minimal increase of leakage in organs with continuous 
endothelium (heart, muscle, lung) was detected [57]. 
Interestingly, vascular permeability was unaltered in the 
liver sinusoids and glomeruli of PLVAP-knockout mice, 
indicating that PLVAP deletion does not alter barrier 
integrity in the porous endothelial cells that are known 
to lack FDs [57]. Collectively, these findings suggest 
that hypoproteinemia and hypoalbuminemia in PLVAP-
knockout mice are the result of increased vascular leak-
age in fenestrated endothelium [57].
Recently, these results in mice were supported by two 
case studies of infants who had a homozygous non-sense 
mutation in the PLVAP gene, and died at 5 months and 
15 days of age [89, 90]. As a consequence of this muta-
tion, PLVAP was targeted for degradation by non-sense-
mediated mRNA decay, leading to complete absence 
of SDs and FDs in endothelial cells [89]. Comparable to 
the phenotype observed in PLVAP-knockout mice, these 
patients suffered from severe protein-losing enteropathy 
which is a pathological condition characterized by exces-
sive loss of plasma proteins in the gastrointestinal tract, 
and eventually death [89, 90].
Together, these observations strongly indicate that 
lack of PLVAP expression leads to leakage in vessels 
with fenestrated endothelium, in particular of proteins. 
Based on the localization of PLVAP in diaphragms, it 
is tempting to speculate that PLVAP regulates vascular 
permeability by providing a size limitation or filter func-
tion to fenestrae and caveolae, allowing the passage of 
water and solutes but preventing passage of macromol-
ecules (Fig. 2). The ultrastructural images of Bearer et al. 
[54] showed that the maximum arc length between the 
radial fibrils is 5.46 nm on average. However, the distance 
between the radial fibrils may be larger than the calcu-
lated average distance since the electron microscopic 
technique that was used shows a larger width of the 
radial fibrils of 1–2 nm beyond its real size due to metal 
shadowing [54]. According to the assumed wheel-like 
incorporation of PLVAP in diaphragms with a distance 
between adjacent radial fibrils at the rim of approxi-
mately 6  nm [54, 60] and the physiological upper limit 
pore size of fenestrated endothelium and the underlying 
lamina basalis [57, 91], it has been postulated that lack 
of PLVAP fibrils in diaphragms results in vascular leak-
age of plasma proteins with molecular diameters between 
6 and 30 nm, which includes all plasma proteins except 
large protein complexes or lipoprotein particles such as 
chylomicrons [57].
Although it has been assumed that SDs and FDs have 
a similar architecture and composition, several studies 
indicate that the different types of diaphragms have dif-
ferential biochemical properties. While SDs lack anionic 
sites, FDs are characterized by high numbers of anionic 
sites [92]. This difference in charge results in an extra 
layer of selectivity of permeability, presumably lead-
ing to impermeability for anionic (plasma) proteins at 
FDs, whereas SDs may allow the passage of anionic mol-
ecules [92]. These different biochemical characteristics 
may be related to the glycocalyx covering the luminal 
side of these diaphragms, as proteases and heparinase 
can remove the anionic sites on FDs [93]. On the other 
hand, despite the fact that it is well established that the 
endothelial cell surface is negatively charged, the content 
of anionic sites on FDs appears to be considerably higher 
compared to that of the adjacent plasma membrane [91]. 
Therefore, it is tempting to speculate that PLVAP binds to 
different glycoproteins in different vascular beds, which 
may alter the chemical composition of the endothelial 
opening and selectivity towards molecules. However, it is 
also possible that other proteins besides PLVAP are pre-
sent in diaphragms and this may differ in SDs and FDs.
The lack of increased permeability in the continu-
ous endothelium of the lung of PLVAP-knockout mice 
in the study of Stan et al. [57], where caveolae are nor-
mally covered with SDs, made the authors conclude 
that the absence of PLVAP does not directly induce 
leakage of plasma proteins via caveolae. The apparent 
lack of a significant role of SDs in regulating protein 
extravasation is consistent with our recent observa-
tions, which show that basal vascular permeability for 
proteins is similar in the continuous endothelium of the 
dorsal skin of heterozygous Plvap mice as compared to 
wild-type mice [Van der Wijk et al., submitted]. The dif-
ference in relevance of PLVAP in SDs and FDs may be 
explained by the morphological differences of caveolae 
and fenestrae. Lack of diaphragms in fenestrae results 
in pores that directly connect the capillary lumen and 
the underlying tissue without any permselective barrier, 
allowing diffusion of macromolecules out of the circu-
lation. In contrast, lack of SDs may modulate the entry 
of macromolecules into vesicles, but vesicular traffick-
ing is still dependent on other proteins which include, 
among others, caveolin-1, dynamins and SNARE pro-
teins that regulate caveolae formation, scission and 
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fusion, respectively [94–96]. Alternatively, lack of 
FDs may considerably diminish the natural repellence 
against anionic proteins, which may explain why the 
leakage in fenestrated endothelium is so prominent. 
On the other hand, in vitro findings suggest that knock-
down of PLVAP expression in human umbilical vein 
endothelial cells leads to a twofold increase in trans-
endothelial electrical resistance  and decreased per-
meability for both 70  kDa tracers and 766  Da tracers 
[28]. This indicates that lack of PLVAP in non-barrier 
endothelium may induce barrier-like properties, which 
is accompanied by a very low rate of vesicular transcy-
tosis and may possibly counteract increased entry of 
macromolecules in vesicles when caveolae lack SDs. 
It is evident that PLVAP as a structural component of 
diaphragms has an important filter function. Therefore, 
we hypothesize that vesicular transcytosis in PLVAP-
knockout mice is reduced to prevent aberrant transport 
of molecules across the barrier, and thus permeability 
does not increase when SDs are not present in continu-
ous endothelium.
Besides acting as a physical sieve that controls trans-
cytosis of molecules in mature endothelium, diaphragms 
may also give structural stability to caveolae and/or 
fenestrae during embryogenesis. In a C57BL/6N back-
ground, PLVAP-knockout mice die before birth as a 
consequence of subcutaneous edema and hemorrhages 
[55]. Transmission electron microscopy revealed that 
loss of SDs in subcutaneous capillaries of PLVAP-defi-
cient embryos leads to vessels with large openings that 
are covered by degranulated thrombocytes [55]. This 
indicates that PLVAP may provide mechanical strength 
to the capillaries during embryogenesis, preventing ves-
sels to become damaged during the dramatic remodeling 
events of angiogenesis and thus to prevent hemorrhages 
[55]. This function of PLVAP seems plausible as lack of 
FDs results in aberrant morphological phenotypes of 
fenestrae with widths of 50–120 nm in PLVAP-knockout 
mice and 20–400 nm in an in vitro assay instead of the 
typical 60–80  nm [57, 97], indicating that PLVAP may 
also give mechanical support to fenestrae. Alternatively, 
the lack of vessel wall integrity as observed in PLVAP-
knockout mice may also be the consequence of impaired 
angiogenesis, as PLVAP plays an important role in this 
process [36].
It seems not very likely that PLVAP gives structural sta-
bility to mature endothelium, since there are also cave-
olae and fenestrae known to lack diaphragms in mature 
endothelium such as that of the kidney glomeruli and 
liver sinusoids [57]. PLVAP is present in these endothe-
lia during embryogenesis [97, 98], which could be related 
to its function in mechanical stabilization. On the other 
hand, this may imply that controlled permeability is 
important during embryonic development.
Taken together, these results indicate that PLVAP is a 
crucial regulator of vascular permeability in non-barrier 
endothelium in both embryos and adults. During embry-
ogenesis, PLVAP may directly promote angiogenesis or 
give mechanical support to capillaries which prevents the 
formation of leaky vessels after the dramatic remodeling 
steps during angiogenesis. In the mature vascular sys-
tem, PLVAP has a crucial gatekeeping function, allowing 
the entry of small molecules but limiting leakage of large 
plasma proteins.
It is interesting to note that in a recent study, we found 
that reduced PLVAP levels in heterozygous Plvap mice 
protects the continuous endothelium of the dorsal skin 
from both VEGF- and histamine-induced permeabil-
ity [Van der Wijk et  al.,  submitted]. This suggests that 
PLVAP may function downstream of multiple permeabil-
ity-inducing molecules.
PLVAP in barrier endothelium
PLVAP expression is absent in mature endothelium with 
BBB and BRB properties (Table  2) [23, 24]. However, 
PLVAP is widely expressed in endothelia in the brain and 
retina during embryogenesis or postnatal development 
[30, 68, 99, 100, Van der Wijk et al., submitted], which is 
likely linked with an important function during vascu-
lar development (Fig. 3). PLVAP expression is negatively 
correlated with the maturation of the vasculature and 
acquisition of a functional BBB and BRB [30, 68, 99, 100]. 
Correspondingly, PLVAP expression in the BBB and BRB 
is induced in pathological conditions associated with vas-
cular leakage such as diabetic retinopathy [25, 37, 75], 
brain ischemia [35, 36] and brain tumors [22, 23, 35]. 
Collectively, these observations suggest that absence of 
PLVAP expression in barrier endothelium is essential for 
the formation and maintenance of the BBB and BRB.
This is in agreement with the recent observation 
that suppressed transcellular transport is essential for 
the maturation of the BBB and BRB [101–103]. While 
immature and leaky retinal vessels have a functional 
tight junctional network that is similar to that of mature 
endothelium, a significant reduction in the number of 
vesicles governs maturation of the endothelium to form 
a functional BRB [101]. Further research is needed 
to establish the exact function of PLVAP in vascular 
development.
In contrast, it is relatively well-established that 
PLVAP plays a functional role in BBB and BRB break-
down in pathological conditions (Fig.  4). With the use 
of short hairpin RNA (shRNA)-mediated knockdown 
of PLVAP expression, it was shown that PLVAP inhi-
bition reduces VEGF-induced loss of BRB integrity as 
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shown in a  trans-endothelial electrical resistance  assay 
[28]. Moreover, inhibition of PLVAP expression signifi-
cantly reduced VEGF-induced permeability of 70  kDa 
tracers but not of 766  Da tracers in an in  vitro model 
of retinal leakage [28, 104]. Correspondingly, siRNA-
targeting of PLVAP expression reduced vascular per-
meability in the oxygen-induced retinopathy (OIR) 
mouse model as shown by decreased extravasation of 
fluorescent tracers (70  kDa) and fluorescein angiog-
raphy [28]. Large molecules (70  kDa) are expected to 
cross the endothelial barrier via transcellular transport, 
whereas small molecules (766  Da) cross the barrier via 
the paracellular pathway. Thus, these findings suggest 
that (VEGF-induced) leakage via the transcellular path-
way is dependent on PLVAP expression. Correspond-
ingly, shRNA-mediated knockdown of PLVAP expression 
did not prevent VEGF-induced alterations in endothe-
lial junction integrity [28]. However, stress fiber forma-
tion was significantly reduced. Ultrastructural analysis 
revealed that knockdown of PLVAP expression in human 
retinal explants blocks VEGF-induced caveolae forma-
tion to basal levels [28], suggesting that PLVAP induces 
leakage by enabling formation of caveolae, probably with 
PLVAP-containing SDs. The observation that inhibition 
of PLVAP expression does not modulate basal caveolae 
numbers is in agreement with the study of Herrnberger 
et al. [55], that did not observe a reduction in the number 
of caveolae in endothelial cells of Plvap-deficient mice. 
As previously emphasized, vesicular trafficking is a com-
plex process that requires the need of multiple proteins 
and molecules [94–96], indicating that increased num-
bers of caveolae do not necessarily implicate increased 
transcytosis. However, VEGF has been shown to induce 
the expression of several important genes involved in the 
transcellular transport pathway [62] and promotes cav-
eolae-mediated transcytosis in vivo [85], which strongly 
indicates that this argument is invalid during pathological 
Fig. 3 PLVAP regulates vascular development and function. a Absence of Wnt and Norrin ligands for the Lpr5/Frzd receptor complex results 
in inactive canonical β-catenin signaling in non-barrier endothelium and in early embryonic stages in barrier endothelium. As a consequence, 
cytosolic β-catenin is targeted for proteolytic degradation through phosphorylation by the “β-catenin destruction complex”, which consists of 
the APC/axin/GSK3b-complex. Low levels of β-catenin allow upregulation of PLVAP expression in endothelial cells. However, it is unknown how 
PLVAP expression is upregulated during vascular development. PLVAP expression in the developing vasculature is essential during angiogenesis. 
PLVAP may directly promote angiogenesis or give mechanical support to capillaries, which prevents the formation of leaky vessels after the drastic 
remodeling steps of angiogenesis. b The canonical β-catenin signaling pathway is active in late embryonic stages in barrier endothelium. In the 
presence of Wnt or Norrin ligands, the “β-catenin destruction complex” is inhibited which results in the accumulation of β-catenin in cells. Nuclear 
β-catenin induces the transcription of β-catenin-target genes, which results in the downregulation of PLVAP expression. Low levels of PLVAP 
expression induce maturation of the BRB and BBB. EC endothelial cell (Adapted from [68])
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vasogenic edema formation, as long as PLVAP is also 
expressed.
The exact molecular mechanisms by which PLVAP 
modulates caveolae formation or how the presence of 
caveolae with PLVAP-containing SDs allows barrier 
loss remain still unknown. Previous research indicates 
that VEGFR2 is localized in caveolae [77, 78]. Thus, 
PLVAP may modulate vascular permeability and caveo-
lae formation via regulating the availability of VEGFR2 
in cells, as a primary or secondary mechanism. Inter-
estingly, PLVAP has been shown to interact with 
NRP-1, which is an important co-receptor in VEGFR2 
signaling regulating VEGFR2 surface expression [45, 
105]. An intriguing possibility is that PLVAP affects 
the stability of VEGFR2/NRP-1 complexes, and thus 
VEGFR2-mediated signaling. At the same time, PLVAP 
expression is induced in a VEGFR2-dependent man-
ner [61]. Thus, this opens the interesting possibility of a 
positive feedback loop that promotes breakdown of the 
BBB and BRB. Further research is needed to elucidate 
how PLVAP regulates VEGF-dependent caveolae for-
mation and increased permeability.
Although we have considered paracellular and trans-
cellular transport as two independent transport mecha-
nisms in this review so far, it is becoming clear that 
complex interdependency between these two path-
ways exist [82, 106]. In line with this insight, despite the 
direct association of PLVAP with transcellular transport, 
PLVAP appears to modulate paracellular transport as 
well. A direct indication that PLVAP plays a functional 
role in the paracellular pathway comes from the obser-
vation that PLVAP is able to regulate the number of 
fenestrae and caveolae in cells [28, 55, 58]. Although the 
exact molecular events behind the biogenesis of these 
structures is not known, it is evident that it requires reor-
ganization of the cytoskeletal framework [97]. It would 
be interesting to determine whether PLVAP, with its 
intracellular connections to the cytoskeleton, affects the 
dynamic nature of the cytoskeleton, and subsequently 
intracellular gap formation. Interestingly, previous work 
Fig. 4 PLVAP induces vascular leakage through promoting VEGF-dependent caveolae formation. a The BBB and inner BRB are hallmarked by high 
trans-endothelial electrical resistance (TEER), which is the result of an elaborated junctional network, limited presence of caveolae and absence 
of fenestrae. In physiological conditions, the availability of VEGFR1 homodimers predominantly localized at the luminal side of the BBB and BRB 
induces important vascular protective functions [120]. In contrast, VEGFR2 homodimers at the abluminal side [120], which are probably present at 
a very low concentration under physiological conditions, as VEGFR2 is usually not detectable by immunohistochemistry in brain and retinal vessels 
[74, 75], mediate vascular leakage (not shown). b In pathological conditions such as diabetic retinopathy, tissue VEGF-A levels are high. In addition, 
VEGFR2 and VEGFR3 are highly expressed in retinal vessels of diabetic patients. Together, this results in VEGFR2/PI3K/p38MAPK-dependent PLVAP 
expression and formation of caveolae, which promotes leakage of plasma proteins and edema formation. EC endothelial cell, PC pericyte
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has shown that inhibition of PLVAP expression in bovine 
retinal endothelial cells significantly reduced stress fiber 
formation after VEGF stimulation, indicating that PLVAP 
may regulate intracellular gap formation [28]. Although 
this function of PLVAP may operate via its suspected 
link to actin-binding proteins, it should be noted that 
knockdown of PLVAP expression had only limited effects 
on stress fiber formation in unstimulated cells [28]. This 
indicates that VEGF plays a central role in this process 
and that the role of PLVAP is indirect. A striking phe-
notype observed in these cells was that knockdown of 
PLVAP expression significantly blocked VEGF-induced 
caveolae formation, which led to the hypothesis that 
PLVAP regulates VEGFR2 availability [28]. Interestingly, 
VEGF-A has been shown to induce activation of RhoA, 
which is well known for its function in stress fiber forma-
tion and cellular contractility [107, 108]. Hence, PLVAP 
may modulates stress fiber formation via induction of 
VEGFR2-dependent Rho GTPase signaling in cells, 
which is an interesting avenue to be explored in future 
research. Moreover, in a recent study we have found that 
expression of tight junctions and adherens junctions is 
altered in the retina of heterozygous Plvap mice [Van der 
Wijk et al., submitted]. Although it is not known how this 
altered expression is translated into functional junctional 
characteristics, it indicates that PLVAP affects paracellu-
lar transport as well.
In short, PLVAP plays an important functional role in 
VEGF-induced BBB and BRB breakdown by regulating 
the number of caveolae with PLVAP-containing SDs. 
Although the sieving function of PLVAP during mac-
romolecular transport in fenestrated endothelium is 
well established, PLVAP regulates vascular permeabil-
ity in multiple and complex additional ways that remain 
incompletely understood.
Therapeutic perspective for cerebral edema 
and diabetic macular edema
Treatment approaches for vasogenic cerebral edema 
and DME remain limited. Available options for cerebral 
edema include osmotherapy, corticosteroids and surgery 
[109]. However, osmotherapy only has transient effects, 
and its overall effectiveness remains elusive [110]. In con-
trast, corticosteroids are well-known to reduce cerebral 
edema, but therapy is associated with numerous severe 
side effects that may persist after treatment [6]. For this 
reason, the identification of novel therapeutic targets for 
cerebral edema is of high clinical importance. Several 
studies demonstrate that VEGF inhibition reduces cer-
ebral edema that is caused by ischemic stroke and brain 
tumors [4, 8, 9]. However, VEGF is an important sign-
aling molecule known to regulate pleiotropic cellular 
responses including neuronal survival and function [12, 
14, 18], indicating that reduction of VEGF levels may 
have significant clinical consequences. In addition, sys-
temic anti-VEGF therapy in cancer patients is associated 
with a high risk of stroke and other arterial thrombo-
embolic events [111, 112].
Apart from the management of risk factors such as 
hyperglycemia and hypertension [113], current treatment 
options for DME consist of anti-VEGF agents, corticos-
teroids and laser photocoagulation. Laser photocoagu-
lation has remained the standard care of treatment for 
over 30  years, but currently anti-VEGF therapy is the 
first line of treatment for DME [11]. However, agents 
that block VEGF do not target the initial upstream fac-
tors that lead to a compromised barrier which makes 
repeated injections (every 4–6  weeks) necessary [17]. 
In addition, a tight balance between VEGF and the pro-
fibrotic growth factor termed connective tissue growth 
factor (CTGF) is present in the eye [15, 114]. Anti-VEGF 
therapy in patients with DME accompanied by severe 
proliferative DR has been shown to cause a shift in bal-
ance of these growth factors, favoring CTGF levels, and 
causing retinal fibrosis [15]. Recently, it was shown that 
repeated intravitreal anti-VEGF injections induces reti-
nal neurodegeneration and increased vascular leakage 
in Akita mice  (Ins2Akita) [17]. Thus, this suggests that 
long-term anti-VEGF therapy induces retinal damage, 
which may eventually have significant impact on visual 
function. Although the effects of long-term anti-VEGF 
therapy in the brain remain unknown, the same charac-
teristics of brain and retinal barrier endothelium and the 
observed neurodegenerative effects in the study of Hom-
brebueno et al. [17] indicate that long-term therapy may 
also induce serious side effects in the brain.
In contrast to VEGF which has effects on multiple cell 
types, PLVAP is only expressed in endothelial cells, where 
it modulates caveolae formation and possibly VEGFR2 
availability [28]. Consequently, targeting PLVAP expres-
sion in brain and retinal endothelial cells may inhibit 
downstream responses of VEGF and of other mediators 
in endothelial cells without altering cell survival of neu-
rons [12, 14, 18]. Together with the striking observation 
that PLVAP inhibition significantly reduced vascular 
leakage of large macromolecules in vitro and in vivo [28], 
it strongly indicates that anti-PLVAP therapy may hold 
great potential as a safer novel treatment option for vaso-
genic cerebral edema and DME.
The widespread expression of PLVAP in non-barrier 
continuous endothelia and the crucial functions of 
PLVAP as a regulator of vascular homeostasis in fenes-
trated endothelium indicate that systemic targeting of 
PLVAP is not recommended. However, the ease of local 
drug delivery in the eye, and the limited fluid and molec-
ular exchange between the eye and the rest of the body 
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indicate that local PLVAP inhibition is achievable. For 
instance, PLVAP expression can be inhibited via intra-
vitreal injections and slow-release drug delivery systems 
such as implantable micropumps [115] or biodegrad-
able polyesteramide microspheres [116]. In contrast to 
the eye, local drug delivery to the brain may be more 
problematic. However, in the case of tumor-related cer-
ebral edema, which often requires surgery to remove 
as much as possible tumor tissue, anti-PLVAP therapy 
may be implemented during surgery to restore the func-
tional properties of the BBB to prevent relapse of edema 
formation.
Further investigations of the therapeutic rationale and 
possibilities of anti-PLVAP therapy is warranted. Inter-
estingly, PLVAP has been shown to modulate angiogen-
esis as well [36], which indicates that PLVAP is also a 
target for conditions associated with angiogenesis such as 
age-related macular degeneration, proliferative diabetic 
retinopathy and cancer.
Therapeutic perspective: targeted drug delivery 
via caveolae
Besides the potential to restore the function of barrier 
endothelia via inhibition of PLVAP expression, PLVAP 
may also be exploited to achieve targeted drug deliv-
ery across the BBB and BRB in pathological conditions. 
In a recent study, the therapeutic enzyme superoxide 
dismutase (SOD) was conjugated to antibodies against 
PLVAP with the ultimate goal to target SOD to caveolae 
of endothelial cells of pulmonary vessels, as the target 
substrate of the enzyme is present in endothelial vesicles 
[117]. Interestingly, SOD conjugated to PLVAP antibod-
ies more efficiently blocked lipopolysaccharide-induced 
pulmonary inflammation than SOD conjugated to 
endothelial cells via CD31 [117]. It is interesting to assess 
whether such type of drug delivery has potential for the 
BBB and BRB.
Concluding remarks
PLVAP is an important regulator of vascular permeabil-
ity during embryogenesis, and after birth in fenestrated 
endothelium and in pathological conditions, in particu-
lar of macromolecules. Although the sieving regulatory 
function of PLVAP as a molecular component of dia-
phragms remains comprehensible, it remains incom-
pletely understood how PLVAP modulates breakdown 
of the BBB and BRB. Previous research indicates that 
PLVAP induces vascular permeability via promoting 
VEGF-dependent caveolae formation, but the molecu-
lar mechanisms remain unclear [28]. Furthermore, very 
little is known how VEGF induces PLVAP expression. 
There are indications that this occurs via a VEGFR2/
PI3K/p38MAPK-dependent signaling pathway [61], but 
it remains unknown which transcriptional regulators 
are involved in this process. More research is needed to 
better understand the underlying molecular and cellu-
lar mechanisms that link PLVAP to vascular leakage and 
breakdown of the BBB and BRB. Nevertheless, after dec-
ades of functioning as histological marker for endothe-
lium in normal tissues outside the brain and eye,   and 
in pathological leakage in the brain and eye without a 
known molecular substrate, the first functional evidence 
has now been provided that PLVAP plays a pivotal role 
in VEGF-induced BRB permeability. Together with the 
selective expression of PLVAP in the BBB and BRB dur-
ing pathological conditions, PLVAP emerges as a novel 
promising therapeutic target to prevent the clinical bur-
den of vasogenic cerebral edema and DME.
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